Sirtex Medical Inc.

Sirtex Medical Inc., a for-profit medical device manufacturer based in Woburn, Massachusetts, supplies Y-90 SIR-Spheres resin microspheres and related selective internal radiation therapy (SIRT) devices to federal healthcare agencies as a prime contractor across 267 recent awards worth a combined $41.8 million in potential value. The company competes without set-aside designation in full and open federal procurements and holds no certifications as a small business, 8(a) firm, or other SBA-designated entity.

Sirtex's federal footprint is dominated by Department of Veterans Affairs and Department of Defense healthcare procurement. The Defense Health Agency leads by potential value at $11.3 million across 31 awards, followed closely by VA Veterans Integrated Service Network 21 at $10.9 million across 64 awards and the Department of the Army Medical Command at $10.1 million across 100 awards. Together, these three customers account for 96% of Sirtex's recent combined potential value. The concentration splits notably between award count and dollars: Army Medical Command places the largest volume of orders but at smaller individual values, while DHA anchors the largest dollars per award. Sirtex maintains active relationships across ten distinct federal customer agencies, including smaller VISN networks (8, 17, 19, 22) within the VA system.

Sirtex's product line maps to three dominant NAICS categories reflecting the radiopharmaceutical nature of its work: Irradiation Apparatus Manufacturing (81 awards), Pharmaceutical Preparation Manufacturing (79 awards), and Surgical Appliance and Supplies Manufacturing (72 awards). Awards cluster under PSC codes for Drugs and Biologicals (144 awards) and Medical and Surgical Instruments and Supplies (99 awards). Recent representative work includes a $487,056 delivery order from VA VISN 22 for Y-90 SIR-Spheres microspheres (awarded January 1, 2026, performance through December 31, 2026), a $551,117 total small business set-aside purchase order from the Defense Health Agency for Y-90 SIR-Spheres resin microspheres (July 8, 2024, performance through July 7, 2025), and a $400,595 purchase order from VA VISN 19 for Y-90 microsphere doses and ancillary supplies supporting treatment of unresectable metastatic liver tumors (April 21, 2022).

Sirtex holds three significant parent vehicles anchoring its federal work. A single-award Veterans Integrated Service Network 19 Blanket Purchase Agreement, effective July 15, 2025 through July 14, 2028, carries a $708,270 ceiling and has generated five BPA calls to date totaling $236,715. A single-award Defense Health Agency Blanket Purchase Agreement, awarded June 10, 2025 and effective through June 9, 2030, carries a $1.1 million ceiling. Most substantially, a Veterans Integrated Service Network 22 single-award indefinite-delivery contract awarded January 1, 2026 for Y-90 SIR-Spheres resin microspheres, dose preparation services, and dose draw fees carries a $3.74 million ceiling with performance through December 31, 2026 and option years extending to 2030; two delivery orders have been issued against this vehicle for Phoenix and Tucson VA medical center supply. Additional vehicles include Army Medical Command Blanket Purchase Agreement W81K0012A0013 (61 task orders, $2.1 million combined potential value).

Activity has remained relatively stable year over year across the past five years — eleven to thirteen awards annually from 2022 through 2025 — with five awards worth $1.2 million in combined potential value facing ultimate completion within the next twenty-four months, representing modest recompete exposure. Sirtex operates exclusively as a prime contractor with no recorded subcontract relationships in the source data, and all its work is performed at its Woburn, Massachusetts facility or customer sites (Miami, Phoenix, Tucson, Dallas, Fort Bliss, and other VA and military medical centers). The company has held federal registration as a supplier since at least 2005, establishing it as an established provider of specialized radiopharmaceutical products across the federal healthcare procurement landscape.

Sirtex Medical Inc mission is to improve the quality and longevity of patients' lives by providing innovative interventional oncology solutions.